Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology.

Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas.

Key Stats

• Today's Range: $6.55 to $7.00
• 50-Day Range: $6.28 to $7.80
• 52-Week Range: $3.81 to $37.50
• Volume: 11,465 shs
• Average Volume: 17,321 shs
• Market Capitalization: $11.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Reduce

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 311th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Lyra Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Lyra Therapeutics has a consensus price target of $100.00, representing about 1,328.6% upside from its current price of $7.00.

Amount of Analyst Coverage

Lyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyra Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.87% of the outstanding shares of Lyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 32.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.87% of the outstanding shares of Lyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 32.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.87

News Sentiment

Lyra Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,039.00 in company stock.

Percentage Held by Insiders

Only 3.25% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYRA Stock Analysis - Frequently Asked Questions

How have LYRA shares performed this year?

Lyra Therapeutics' stock was trading at $10.32 at the beginning of the year. Since then, LYRA shares have decreased by 32.2% and is now trading at $7.00.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($5.51) EPS for the quarter, topping analysts' consensus estimates of ($5.79) by $0.28. The firm had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.18 million. Lyra Therapeutics had a negative net margin of 5,043.64% and a negative trailing twelve-month return on equity of 404.56%.

When did Lyra Therapeutics' stock split?

Lyra Therapeutics's stock reverse split before market open on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/05/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Lyra Therapeutics: $100.00
• High Price Target: $100.00
• Low Price Target: $100.00
• Potential Upside/Downside: +1,328.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($29.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$93.43 million
• Net Margins: -5,043.64%
• Pretax Margin: -5,041.17%
• Return on Equity: -404.56%
• Return on Assets: -60.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.78
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: $1.53 million
• Price / Sales: 7.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.86 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 1,640,000
• Free Float: 1,592,000
• Market Cap: $11.48 million
• Optionable: Optionable
• Beta: 0.11